UC San Diego studies using human cell lines and tumors grown in mice provide early evidence that inhibiting RNA-binding proteins, a previously overlooked family of molecules, might provide a new approach for treating some cancers.
UC San Diego School of Medicine researchers discovered gene expression patterns associated with pandemic viral infections, providing a map to help define patients’ immune responses, measure disease severity, predict outcomes and test therapies — for current and future pandemics.
UC San Diego School of Medicine researchers discovered that SARS-CoV-2, or at least its genetic signature, abounds on hospital surfaces, often co-locating with one particular type of bacteria.
Bukata is only the fourth woman in the U.S. to lead a health system’s orthopedic surgery department.
Augmented reality headsets give UC San Diego Health spine surgeons “x-ray vision” during procedures for accurate and personalized implant placement, while keeping their eyes on their patients.
UC San Diego School of Medicine researchers discovered one way in which SARS-CoV-2 hijacks human cell machinery to blunt the immune response, allowing it to establish infection, replicate and cause disease.
UC San Diego researchers found that the chemical inhibitor K777 reduces the coronavirus’ ability to infect cell lines by blocking human enzyme cathepsin L; clinical trials are underway.
UC San Diego researchers discovered that patient survival from sepsis is associated with higher platelet counts, and identified two currently available drugs that protect these blood cells and improve survival in mice with sepsis.
UC San Diego School of Medicine researchers develop an automated process to test city sewage for SARS-CoV-2, allowing them to forecast the region’s COVID-19 caseload one to two weeks ahead of clinical diagnostic reports.
UC San Diego was awarded five COVID-19 Rapid Acceleration of Diagnostics (RADx) projects by the National Institutes of Health totaling nearly $33 million, which will fund efforts that range from managing a large data center to expanding testing in disadvantaged communities.